Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1027 | Interdisciplinary Endocrinology 2 | ECE2019

Immune-related endocrine toxicities in non-small cell lung cancer: predictors of outcome to checkpoint inhibitors?

Poli Roberta , Dumont Clement , Pietrogiovanna Lisa , Servois Vincent , Beaucaire-Danel Sophie , Daniel Catherine , Girard Nicolas , Romano Emanuela , Hescot Segolene

Background: Immune checkpoint inhibitors (ICIs) are approved for the treatment of non-small cell lung cancer (NSCLC) and are associated with specific immune-related adverse events (iRAEs) including endocrine toxicities. However, data concerning the type, occurrence, and dynamics of iRAEs and their predictive value on treatment outcome are lacking. In this study, we evaluated the relation of iRAEs to anti-PD/L1 (programmed cell death protein/ligand-1) ICIs focusing particularly...

ea0049ep883 | Growth hormone IGF axis - basic | ECE2017

A surprising and dramatic neuroendocrine-immune phenotype of mice deficient in Growth Hormone-Releasing Hormone (GHRH)

Farhat Khalil , Bodart Gwennaelle , Renard Chantal , Desmet Christophe , Moutschen Michel , Baron Frederic , Beguin Yves , Salvatori Roberto , Matens Henri , Geenen Vincent

In the framework of close interactions between the immune and neuroendocrine systems, Growth Hormone (GH) has been proposed to exert significant effects on the immune system, but there is not yet a consensus about GH immunomodulatory properties. These studies investigated the immune and anti-infectious response of dwarf Ghrh−/− mice presenting a severe deficiency of the GHRH/GH/IGF-1 axis. In basal conditions, thymic parameters and T-cell respon...

ea0049ep1439 | Thyroid (non-cancer) | ECE2017

A higher frequency of papillary thyroid carcinoma in myotonic dystrophy

Ben Hamou Adrien , Dhaenens Claire Marie , Espiard Stephanie , Benomar Kanza , Tiffreau Vincent , Caiazzo Robert , Aubert Sebastien , Vantyghem Marie Christine

Background and purpose: Type 1 myotonic dystrophy (MD), associates neuromuscular, cardiac, respiratory and endocrine disorders. The aim of this study was to determine the prevalence of thyroid disorders and of any causal factors.Methods: A retrospective single centre study was conducted, between 2000 and 2016, in 127 MD patients, diagnosed by familial genetic screening after informed consent. Clinical examination, TSH assay, 120-min glucose and insulin l...

ea0044p8 | Adrenal and Steroids | SFEBES2016

Full characterisation of adrenal steroidogenesis by liquid-chromatography–mass spectrometry (LC–MS/MS) in metyrapone and/or ketoconazole-treated pituitary/adrenal Cushing’s

Taylor David R , Leong Christine H M , Bhatt Aagna E , Ghataore Lea , Aylwin Simon , Whitelaw Ben , Vincent Royce P

Introduction: Pituitary and adrenal Cushing’s may be managed by pharmacological-inhibition of adrenal steroidogenesis, using metyrapone and/or ketoconazole. Assessment of biochemical control is challenging owing to cross-reactivity in immunoassays (e.g. cortisol and 11-deoxycortisol) leading to over/under-treatment. Off-target effects can also result, e.g. hyperandrogenism/mineralocorticoid hypertension (increased 11-deoxycorticosterone/DOC). LC-MS/MS analysis is free fro...

ea0041ep615 | Endocrine tumours and neoplasia | ECE2016

Genetic predisposition to breast cancer occurring in a male-to-female transsexual patient

Potorac Iulia , Corman Vinciane , Manto Florence , Dassy Sarah , Segers Karin , Thiry Albert , Bours Vincent , Daly Adrian F , Beckers Albert

Introduction: Breast cancer affects less than 1% of all male cancer patients. In 5–20% of cases, genetic predisposition is involved, mostly due to mutations of the BRCA2 gene. Hormonal imbalance between oestrogens and androgens is another predisposing factor. Male-to-female (MtF) transsexual patients usually undergo long-term cross-sex hormone therapy, which could expose them to higher risks of developing hormonally-dependent cancers.We rep...

ea0041ep889 | Pituitary - Clinical | ECE2016

Combined treatment with octreotide LAR and pegvisomant in patients with gigantism – acromegaly: clinical evaluation and genetic screening

Rostomyan Liliya , Mangupli Ruth , Castermans Emilie , Caberg Jean-Hubert , Camperos Paul , Cuauro Elvia , Bours Vincent , Daly Adrian F , Beckers Albert

Pituitary gigantism is a rare condition caused by growth hormone secreting lesions, where treatment is usually challenging, especially in cases with genetic predisposition. Aim: We studied a gigantism cohort from Venezuela for genetic defects and their response to treatment. Subjects: 160 somatotropinoma patients were evaluated at the University hospital (from 1985–2015); eight (6M) were diagnosed with acrogigantism and underwent genetic analysis including aCGH for Xq26.3...

ea0059p142 | Neuroendocrinology and pituitary | SFEBES2018

A single-centre audit of treatment outcomes in 185 acromegaly patients under regular follow-up

Muhammad Shoaib Khan Sardar , Mola Laura , Perez-Fernandez Leticia , Vincent Alex , Grossman Ashley , Cudlip Simon , Jafar-Mohammadi Bahram , Pal Aparna

Transsphenoidal adenomectomy (TSA) is the recommended primary therapy in most patients with acromegaly and results in remission for majority of microadenomas and a proportion of macroadenomas depending on extent of surgically accessible disease. Acromegaly is associated with significant mortality and morbidity, hence a combination of treatment modalities may be needed to achieve disease control.Methods: A retrospective casenotes review was conducted and ...

ea0037ep194 | Reproduction, endocrine disruptors and signalling | ECE2015

Evaluation of an automatic referral system for inpatients with hyponatraemia: prompt referral leads to active intervention

Mannan Jayamalathy Mannar , Joshi Mamta , Vincent Roy , Sherwood Roy , Jafar-Mohammadi Bahram , Gilbert Jackie , Whitelaw Benjamin , Aylwin Simon

Inpatients with hyponatraemia have a high mortality and longer length of stay. We instituted a system of automatic referral to the endocrinology team where any inpatient with a serum (Na+) ≤125 mmol/l was referred automatically from their biochemical results.Aims: We evaluated the diagnosis, management, and outcome of the patients referred with hyponatraemia over 6 months.Methods: Data were prospectively captured e...

ea0035p948 | Steroid metabolism and action | ECE2014

Changes in serum steroid concentrations in relation to fat distribution and insulin resistance in women with polycystic ovarian syndrome

Ibanichuka Jacqueline , Vincent Royce P , Ghataore Lea , Taylor Norman F , Millward Ann , Pinkney Jonathan H , Stenhouse Elizabeth

Background: Polycystic ovarian syndrome (PCOS) affects 5–10% of women of reproductive age. Hyperandrogenism and hyperinsulinaemia have been attributed to the pathophysiology of PCOS. The aim of this study is to evaluate the effect of fat distribution and insulin resistance on steroid metabolism in PCOS.Methods: The study recruited 20 PCOS and 20 matched controls. Fat distribution was assessed by waist circumference, skin fold measurements, and body ...

ea0031p74 | Clinical practice/governance and case reports | SFEBES2013

Spironolactone interference in the immunoassay of androstenedione in a patient with a cortisol-secreting adrenal adenoma

Broderick Deirdre , Crowley Rachel K , O'Shea Triona , Boran Gerard , Conlon Kevin , Maher Vincent , Gibney James , Sherlock Mark

A 48-year-old man was referred for investigation of uncontrolled hypertension on four agents (olmesartan, felodipine, hydrochlorothiazide and spironolactone) and a 3 cm right-sided adrenal adenoma (pre-contrast Hounsfield units 25). Endocrine investigation for the hypertension and adrenal mass included: androstenedione 19.9 nmol/l 2.8–10.5) (elevated on two occasions on a Siemens Coat-A-Count assay), DHEA 0.7 μmol/l (2.1–15.2), 1 mg overnight dexamethasone suppr...